By Barbara Obstoj-Cardwell. Editor
Cambridge, USA-based Agios Pharmaceuticals last week agreed to sell its royalty rights on Servier’s sales of vorasidenib for up to $1.1 billion to Royalty Pharma. US pharma giant Merck & Co last Wednesday announced its intention to acquire EyeBio for up to $3 billion along with its ophthalmology pipeline. On the research front, biotech Insmed announced positive Phase III results for its bronchiectasis candidate brensocatib. Human Immunology Biosciences (HI-Bio), the subject of a $1.8 billion takeover bid from Biogen, released positive results for its CD38 antibody felzartamab in the treatment of IgA nephropathy. Also, Gilead Sciences released Ph III trial results for Trodelvy in bladder cancer, which failed to meet its primary endpoint.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze